Last reviewed · How we verify
Glycopyrronium MDI 7.2 micrograms
Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to bronchodilation.
Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to bronchodilation. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Glycopyrronium MDI 7.2 micrograms |
|---|---|
| Sponsor | Pearl Therapeutics, Inc. |
| Drug class | Anticholinergic |
| Target | Muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
This results in relaxation of smooth muscle in the airways, making it easier to breathe for individuals with chronic obstructive pulmonary disease (COPD). By blocking muscarinic receptors, glycopyrronium reduces the constriction of airway smooth muscle, thereby improving lung function.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Dry mouth
- Headache
- Nausea
- Dizziness
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycopyrronium MDI 7.2 micrograms CI brief — competitive landscape report
- Glycopyrronium MDI 7.2 micrograms updates RSS · CI watch RSS
- Pearl Therapeutics, Inc. portfolio CI